Search

Your search keyword '"Earle C"' showing total 19 results
Start Over Author "Earle C" Journal value in health
19 results on '"Earle C"'

2. EE234 Economic Analysis of the Pronto Study

Author

Seung, S.J., primary, Saherawala, H., additional, Nguyen, L., additional, Gatley, J.M., additional, Liu, N., additional, Bayani, J., additional, Barker, S., additional, Bartlett, J., additional, Berman, D.M., additional, Earle, C., additional, Loblaw, A., additional, and Mittmann, N., additional

Published
2023
Full Text
View/download PDF

19. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.

Author

Lang K, Marciniak MD, Faries D, Stokes M, Buesching D, Earle C, Treat J, Babineaux S, Morissette N, Thompson D, Lang, Kathleen, Marciniak, Martin D, Faries, Douglas, Stokes, Michael, Buesching, Don, Earle, Craig, Treat, Joseph, Babineaux, Steve, Morissette, Nathalie, and Thompson, David

Abstract

Objectives: The purpose of this study was to identify total lifetime medical-care costs and costs associated with first-line chemotherapy treatment among older patients with stage IIIB/IV non-small-cell lung cancer treated with commonly used two-drug chemotherapy ("doublet") regimens in the United States. Methods: Study patients included individuals aged 65 years and older who received a diagnosis of stage IIIB/IV non-small-cell lung cancer in a Surveillance, Epidemiology and End Results cancer registry between 1997 and 2002 and who received first-line treatment with commonly used doublet regimens. Patients were followed retrospectively in the Surveillance, Epidemiology and End Results-Medicare database to evaluate lifetime medical-care costs and costs while on first-line chemotherapy treatment. Pairwise comparisons of treatment costs were estimated by using nonparametric bootstrap methods. Results: Lifetime medical-care costs totaled approximately $70,000 and on-treatment costs for first-line chemotherapy totaled approximately $30,000 among study patients and were dominated by hospitalization and physician costs. Lifetime costs were significantly higher among patients treated with first-line cisplatin/carboplatin (platinum) plus a taxane compared with those who received platinum plus gemcitabine [difference: $4781 ($1558-$8039)] or other doublet therapy [difference: $5961 ($2333-$9614)]. Total on-treatment costs for first-line chemotherapy were significantly higher among patients treated with platinum plus a taxane compared with those who received platinum plus gemcitabine [difference: $5825 ($3872-$7770)], platinum plus another agent [difference: $5968 ($3995-$7975)], or another doublet therapy [difference: $3663 ($1620-$5740)]. Conclusions: There is a cost differential between first-line doublet regimens in terms of lifetime and on-treatment costs. Although doublet therapy with platinum and a taxane was the most frequently utilized regimen, it was associated with the highest lifetime and on-treatment costs. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results